Linezolid

Hospital Pharmacy

Volumn 35, Issue 9, 2000, Pages 980-993

  Cada, D J ^a   Baker, D E ^a   Levien, T ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CEFPODOXIME; CLARITHROMYCIN; DICLOXACILLIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; NAUSEA; PHASE 4 CLINICAL TRIAL; REVIEW; VERTIGO; VOMITING;

EID: 0033833418     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003500907     Document Type: Review

References (66)

1. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
2. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
3. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
4. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid
5. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
6. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents
7. The in-vitro activity of linezolid (U-100766) and tentative breakpoints
8. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom
9. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
10. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and-susceptible Staphylococcus aureus strains
11. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci
12. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis
13. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis
14. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
15. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
16. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci
17. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae
18. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
19. Comparative in vitro and bactericidal activity, of oxazolidinone antibodies against multidrug-resistant enterococci
20. In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci
21. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
22. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans
23. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
24. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
25. Oxazolidinones: A review
26. An update on the oxazolidinone antibiotics
27. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam
28. Efficacy of linezolid in gram-positive infections: Results from two phase II trials
29. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
30. Successful treatment of persistent vancomycin-resistant Enterococcusfaecium bacteremia with linezolid and gentamicin
31. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms
32. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin)
33. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains